Date:
11/1/18
The properties of long-acting PrEP drugs that reduce the need for daily dosing also presents a new set of challenges if and when people decide to stop.
When LA drugs are used for treatment, this is less of a problem, as HIV positive people will usually be switching to an alternative drug combination.
However, when these drugs are used for PrEP, there will be months – or in some cases years – where there are different concerns from the long time they take to leave the body. In the phase 2 ECLAIR study, 17% of men had detectable cabotegravir levels a year after their final injection of 800 mg IM given on a 12-week schedule.